-+ 0.00%
-+ 0.00%
-+ 0.00%

Dyne Therapeutics grants CMO Douglas Kerr 8,000 restricted stock units

PUBT·10/22/2026 20:11:12
Listen to the news
Dyne Therapeutics grants CMO Douglas Kerr 8,000 restricted stock units
  • Dyne Therapeutics awarded R&D head and CMO Douglas Kerr 8,000 common stock shares on October 20, 2026.
  • Kerr also received stock options to buy 12,000 common stock shares at an exercise price of $16.27 per share.
  • The options expire on October 19, 2036.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001814189-26-000007), on October 22, 2026, and is solely responsible for the information contained therein.